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Summary
Familial hemophagocytic lymphohistiocytosis (FHL),
also known as familial erythrophagocytic lymphohistio-
cytosis and familial histiocytic reticulosis, is a rare au-
tosomal recessive disorder of early childhood character-
ized by excessive immune activation. Linkage of the
disease gene to an ∼7.8-cM region between markers
D9S1867 and D9S1790 at 9q21.3-22 was identified by
homozygosity mapping in four inbred FHL families of
Pakistani descent with a combined maximummultipoint
LOD score of 6.05. This is the first genetic locus to be
described in FHL. However, homozygosity by descent
across this interval could not be demonstrated in an
additional affected kindred of Arab origin, whose max-
imum multipoint LOD score was 0.12. The combined
sample revealed significant evidence for linkage to 9q
markers (LOD score with heterogeneity, 5.00). Identi-
fication of the gene(s) involved in the pathogenesis of
FHL will contribute to an understanding of the control
of T-lymphocyte and macrophage activation, which is
central to homeostasis in the immune system.
Introduction
Familial hemophagocytic lymphohistiocytosis (FHL;
MIM 267700), first described by Farquhar and Clai-
reaux (1952), is a lethal disorder of immune regulation,
characterized by uncontrolled T-lymphocyte and mac-
rophage activation, with an estimated incidence of 1/
50,000 live births (Henter et al. 1991c;Hirst et al. 1994;
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Arico et al. 1996). Inheritance is autosomal recessive.
Infiltration of the liver, spleen, bone marrow, and central
nervous system by activated T cells and macrophages
results in a multisystem disorder with onset in early in-
fancy, which—in the absence of treatment with epipo-
dophyllotoxins, immunosuppressive agents, or bone
marrow transplantation—progresses rapidly, with a me-
dian survival of 2 mo (Janka 1983; Fischer et al. 1985;
Blanche et al. 1991).
Cardinal clinical features include fever, hepatospleno-
megaly, cytopenia, and neurological abnormalities fre-
quently accompanied by hypofibrinogenemia, hypertri-
glyceridemia, and hyperferritinemia (Henter 1991a).
The characteristic histological finding is a diffuse infil-
tration by lymphocytes and non–Langerhans cell histi-
ocytes, with the latter showing phagocytosis of blood
cells (hemophagocytosis). FHL is included among the
histiocytoses, a heterogeneous group of disorders char-
acterized by abnormal proliferation of antigen-present-
ing or antigen-processing cells (Favara et al. 1997). Re-
cently, the locus for a novel autosomal recessive
histiocytic disorder associated with sensorineural deaf-
ness and joint contractures in a single family was
mapped to chromosome 11q25 (Moynihan et al. 1998).
Thus far, this syndrome, termed “Faisalabad histiocy-
tosis” (MIM 602782), has not been identified in other
kindreds.
The mechanism that underlies failure to abrogate T-
lymphocyte and macrophage activation in FHL is un-
known. Elevation of the concentrations of circulating
cytokines, including g-interferon, interleukin-1 (IL-1),
IL-6, and tumor necrosis factor a, is accompanied by
high serum levels of soluble IL-2 receptor and CD8
(Komp et al. 1989; Henter et al. 1991b; Osugi et al.
1997). These immunological features suggest a failure
to down-regulate proinflammatory cellular immune re-
sponses mediated by T-helper 1 (Th1) lymphocytes,
which leads to sustained macrophage activation. This
pathogenetic model is consistent with the efficacy of T-
lymphocyte–targeted therapy in the form of antithy-
mocyte globulin or cyclosporin A (Stephan et al. 1993;
Abella et al. 1996). Further support for a transregulatory
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Figure 1 Allele segregation of linked and flanking markers in FHL families. Only key subjects are shown. Markers are shown telomeric
to centromeric (top to bottom). Disease-linked haplotypes are boxed. Since limited material was available from the affected individual in kindred
4, we could genotype only markers D9S167, D9S152, D9S1877, and D9S1865 within the critical region in addition to markers D9S1790 and
D9S283.
immune defect in FHL is provided by evidence that al-
logeneic bone marrow transplantation may be curative
in the presence of mixed chimerism, despite limited do-
nor engraftment (Landman-Parker et al. 1993) and the
occurrence of hemophagocytic disorders secondary to T-
lymphoproliferative disorders (Falini et al. 1990). Selec-
tive deficiency in natural killer cell activity (Ladisch et
al. 1982; Perez et al. 1984) and T-cell cytotoxicity (Arico
et al. 1988; Egeler et al. 1996) is frequently observed,
although its relation to the pathogenesis of FHL remains
uncertain.
The genes for Chediak-Higashi and Griscelli syn-
dromes (MIM 214500 and MIM 214450)—autosomal
recessive disorders associated with pigmentary dilution,
cellular immunodeficiency, and evolution in the latter
stages to an “accelerated phase” associated with uncon-
trolled T-cell and macrophage activation—have been
cloned and mapped to chromosomes 1q43 (Barbosa et
al. 1996; Nagle et al. 1996) and 15q21 (Pastural et al.
1997), respectively. Proliferation of activated T cells is
also a feature of the autosomal recessive disorderOmenn
syndrome (MIM 267700), shown recently to result from
impaired genomic rearrangement of antigen receptor loci
due to a mutation of the RAG1 or RAG2 genes at chro-
mosome 11p13 (Villa et al. 1998). Omenn syndrome is
demarcated from FHL and other lymphocyte/macro-
phage activation disorders by a distinct phenotype in
which severe combined immunodeficiency with ery-
throderma, alopecia, lymphadenopathy, liver and spleen
enlargement, protracted diarrhea, and failure to thrive
is accompanied by elevated serum IgE concentrations
and eosinophilia due to oligoclonal expansion of T-
helper 2 lymphocytes, which secrete IL-4 and IL-5. In
contrast to FHL, Th1 lymphocyte activity is suppressed.
The genetic basis of FHL is currently unknown. Hu-
man (Le Deist et al. 1996) and mouse (Schultz et al.
1993; Waterhouse et al. 1995) mutants that resemble
FHL phenotypically have provided a rationale for can-
didate gene approaches. Genetic defects of SHP-1 (a pro-
tein tyrosine phosphatase involved in the down-regu-
lation of signaling in hematopoietic cells), CTLA-4
(which negatively regulates activated T cells), and Fas
(CD95)/Fas ligand (mediators of lymphocyte and mac-
rophage apoptosis) have been excluded in FHL by mu-
tation or linkage analysis (Fischer et al. 1997; Tabrizi et
al. 1998; M. Ohadi, unpublished data). In the present
study, homozygosity mapping localized the gene re-
sponsible for FHL in four affected kindreds of Pakistani
origin to an ∼7.8-cM interval on the long arm of chro-
mosome 9 (bands q21.3-22). An affected kindred orig-
inating from Saudi Arabia exhibited negative multipoint
LOD scores for markers at this interval. This study rep-
resents a first step toward identification of the gene de-
fect(s) in FHL, which promises to illuminate the molec-
ular and cellular basis for regulation of T-lymphocyte
and macrophage activation.
Subjects and Methods
Families
Five consanguineous families originating from Paki-
stan (kindreds 1–4) or Saudi Arabia (kindred 5) were
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included in the study (fig. 1). The diagnosis of FHL ful-
filled the criteria proposed by the Histiocyte Society
(Henter et al. 1991a). The parents were first cousins in
kindreds 1, 3, 4, and 5 and second cousins in kindred
2. In four of the five families (kindreds 1–4), the proband
presented between 1 and 2 mo of age. In kindred 5,
onset of disease in the proband was delayed until 10
mo. All affected children exhibited typical features of
FHL, which included fever, liver and spleen enlargement,
bi- or pan-cytopenia, hypertriglyceridemia, and hypofi-
brinogenemia. We identified hemophagocytosis on ex-
amination of bone marrow and, in two cases (individuals
12 and 16), cerebrospinal fluid. All patients received
treatment with etoposide and corticosteroids alone or in
combination with cyclosporin A. Individual 8 subse-
quently underwent successful allogeneic bone marrow
transplantation from an HLA-identical sibling donor
(individual 6) and remains disease free 54 mo after di-
agnosis. One patient (individual 16) has survived in par-
tial remission with continuing therapy for 15 mo. The
remaining three patients died 9–17 mo after diagnosis
because of disease progression despite treatment.
Healthy siblings were aged 5–18 years at the time of the
study. Blood samples for genetic analysis were collected
after we obtained informed consent. Genotyping was
performed on DNA extracted from paraffin-embedded
tissue obtained from the deceased proband in family 4.
Genotype Analysis
We performed a genomewide screen by means of the
ABI PRISM Linkage Mapping Set version 1 (Perkin-El-
mer Applied Biosystems), consisting of 358 fluorescent-
labeled PCR primer pairs, spaced at intervals of ∼10 cM
and including reverse primer-tailing chemistry (Brown-
stein et al. 1996), selected to amplify highly informative
microsatellite loci from the Ge´ne´thon human linkage
map (Weissenbach et al. 1992; Gyapay et al. 1994; Dib
et al. 1996). The methods we employed have been de-
tailed by Diehl et al. (1990) and Reed et al. (1996). In
brief, we extracted genomic DNA from whole blood in
accordance with a standard protocol (Sambrook et al.
1988), and we extracted DNA from paraffin-embedded
tissue according to the manufacturer’s (Qiagen) protocol
by means of xylene extraction modification.
We performed PCR reactions in 10-ml reactions with
a Perkin-Elmer 9600 thermal cycler. Pooled PCR prod-
ucts were separated on a 4.5% polyacrylamide gel by
electrophoresis on an ABI 377 XL sequencer. The PCR
products were sized by GENESCAN 2.1 and scored by
GENOTYPER 2.0 programs (Applied Biosystems).
Once allele sizes for each microsatellite marker had been
determined for DNA samples from all the families stud-
ied, allele numbers were assigned, and Mendelian in-
heritance was verified.
Statistical Analysis
Individual markers were examined for homozygosity
in the affected members of the FHL families. We per-
formed linkage analysis of the disease locus and markers
at 9q with GENEHUNTER software (Kruglyak et al.
1996). We assumed an autosomal recessive model with
complete penetrance in both sexes and a frequency of
0.004 for the disease allele. Since no information re-
garding the frequency of individual microsatellite alleles
in the Pakistani population was available, we estimated
allele frequencies of the 9q markers by genotyping 50
unrelated, randomly selected, healthy Pakistani subjects.
For the families described, LOD scores were estimated
at 4.61 and 3.67 for markers (assuming five equally fre-
quent alleles) 5 and 10 cM from the disease gene, re-
spectively (Terwilliger and Ott 1994).
Results
Primary Mapping of a Locus for the FHL Gene in
Pakistani Kindreds
The initial genomewide screen of kindreds 1–3 iden-
tified markers D9S167 and D9S283, both located on
chromosome 9q, to be the only markers with consistent
homozygosity in the affected members (fig. 1). The
marker D9S167 showed homozygosity in each of the
affected family members, yielding a combined two-point
LOD score of 3.1. In addition, all affected individuals
were homozygous at marker D9S283, 12 cM telomeric
to D9S167 (although the LOD score was reduced be-
cause of parental homozygosity for this marker),
whereas the affected individuals of families 1 and 3 were
heterozygous at D9S175, 14 cM centromeric toD9S167.
These preliminary findings established linkage of the dis-
ease gene in these families to marker D9S167 and limited
the centromeric boundary of the disease gene interval to
marker D9S175.
Confirmation of Linkage and Delineation of the
Disease Gene Interval by Fine Mapping
Eight microsatellite markers between D9S175 and
D9S283 were selected from the Ge´ne´thon microsatellite
panel (Dib et al. 1996) to confirm and potentially narrow
the disease gene interval. Extended haplotypes con-
structed by use of these markers, the order of which is
consistent with recent genetic linkage maps available
from the National Center for Biotechnology Information
and Center for Medical Genetics web sites, are shown
in figure 1. Regions of homozygosity by descent were
observed in all affected individuals between and includ-
ing D9S264 and D9S1865. Subject 16 in family 3 was
heterozygous at D9S1867 and D9S1790 because of two
recombination events on the maternal side. In this fam-
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Figure 2 HLOD curve for the five FHL families, maximized over the proportion of families linked
ily, an inferred double recombination in the maternal
grandfather narrowed the centromeric limit of the FHL
disease gene interval. A second recombination event in
the mother of the proband (subject 14) between markers
D9S1865 and D9S1790 further resolved the telomeric
boundary, limiting the disease gene interval to ∼7.8 cM
between and excluding markers D9S1867 andD9S1790,
with a combined maximum multipoint LOD score of
4.9.
Inclusion of a fourth affected Pakistani patient in the
study (family 4) revealed homozygosity for markers
D9S167, D9S152, D9S1877, D9S1865, D9S1790, and
D9S283 in the affected individual (fig. 1), which in-
creased the maximum multipoint LOD score to 6.05 in
the interval defined. The limited quantity of archival
necropsy material available precluded further marker
analysis in this case.
Consideration of Locus Heterogeneity in FHL
In the affected member (individual 21) of family 5
(fig. 1) included in the fine mapping, negative multipoint
LOD scores were obtained in the interval
D9S1867–D9S1790 (a maximum of 0.12). Extended
haplotype analysis in the five families resulted in a max-
imum multipoint LOD of 4.40 and a maximum LOD
score with heterogeneity (HLOD) of 5.00 at an estimated
proportion of 0.81 of families linked to chromosome 9q
markers at the interval D9S1867–D9S1790 (fig. 2). The
admixture x2 test of heterogeneity (Smith 1963) gave a
value of 2.76 ( ), providing tentative evidence inP  .1
favor of locus heterogeneity.
Discussion
This study represents the first report of linkage in FHL
and underscores the power of homozygosity mapping to
detect linkage in rare recessive disorders on the basis of
a small number of affected families from a homogeneous
background (Lander and Botstein 1987).
The maximum multipoint HLOD score of 5.00 in the
five families studied identifies a locus for FHL at 9q21.3-
22 in an ∼7.8-cM interval between markers D9S1867
and D9S1790. Among the four kindreds (1–4) that show
linkage (a maximum multipoint LOD score of 6.05) to
this locus, disease-linked haplotypes are shared among
several families (fig. 1). Kindreds 1 and 2 share the hap-
lotype 3–3–1 at D9S1877, D9S1865, and D9S1790, and
kindreds 1–3 share allele 3 at D9S1865. This, however,
does not contribute further to the localization of the FHL
gene at 9q21.3-22, since D9S1877 (3), D9S1865 (3), and
D9S1790 (1) alleles are the ones most frequently en-
countered in the Pakistani population (allele frequencies
of 0.42, 0.61, and 0.50, respectively).
Interestingly, a constitutional pericentric inversion of
chromosome 9 has recently been described in a sporadic
case of hemophagocytic lymphohistiocytosis (Hasle et
al. 1996). It is unlikely that disruption of the FHL gene
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at 9q21.3-22 contributed to pathogenesis in this case,
since the breakpoints of the inversion at 9p23 and 9q31
lie a considerable distance from this locus.
Several possibilities could explain the failure to detect
linkage to chromosome 9q21.3-22 in kindred 5. Lack
of parental informativity within the critical interval
(D9S167, D9S1865, and D9S1790) renders it impossible
to differentiate between homozygosity by state and by
descent at these loci. The occurrence in a consanguineous
kindred of a recessive phenotype, although suggestive,
does not signify homozygosity by descent, per se, and
the possibility, albeit a remote one, that distinct mutant
alleles at the 9q locus segregate in family 5 cannot be
excluded. Alternatively, FHL may exhibit locus hetero-
geneity, as suggested by the result of admixture testing.
The x2 test value obtained (2.76) is compatible, although
not conclusive, in this respect. Heterogeneity with re-
spect to cellular immune dysfunction in FHL (Ladisch
et al. 1982; Stark et al. 1987) is consistent with the
possibility that multiple defects underlie the disease phe-
notype. Since the ethnic background of family 5 varied
from that of the other families included in the study, it
is conceivable that within individual populations defects
of different genes predominate among FHL kindreds.
Further studies of affected families from diverse ethnic
backgrounds will clarify this.
Two genes involved in negative regulation of the cell
cycle—CKS2 (Demetrick et al. 1996) andGAS1 (Del Sal
et al. 1992; Evdokiou et al. 1993)—are located at
9q21.3-22 within the D9S1867–D9S1790 interval. Al-
though they are not specifically implicated in T-cell and
macrophage regulation, a defect in one of these genes
could result in failure to check cellular proliferation,
with persistence of an activated state. Such amechanism,
although speculative, would be consistent with the dif-
fuse lymphohistiocytosis that characterizes FHL. The
observation that deletion or rearrangement of chromo-
some band 9q22 occurs in myeloid leukemias and non-
Hodgkin’s lymphoma, including malignant histiocytosis
(Mitelman et al. 1997), suggests the presence within this
region of one or several genes that play an important
role in the regulation of hematopoietic cell proliferation
or differentiation.
In conclusion, a gene for FHL has been localized by
homozygosity mapping to chromosome 9q21.3-22 be-
tween D9S1867 and D9S1790. Identification of the
causative gene within this interval will facilitate carrier
and prenatal diagnosis of FHL, for which no approach
is currently available, and delineate the mechanisms un-
derlying physiological control of T-lymphocyte andmac-
rophage activation, an essential pathway in regulation
of the immune response.
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